Back
WITHDRAWN: Neutralizing Activity and Viral Escape of Pemivibart by SARS-CoV-2 JN.1 sublineages
Yao, T.; Ma, Z.; Lan, K.; Guo, Y.; Liu, L.
2025-02-26
microbiology
10.1101/2024.11.08.622746
bioRxiv
Show abstract
Withdrawal StatementThe authors have withdrawn this manuscript because of a conflict of interest. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.
Matching journals
●Non-profit
◐University press
○Commercial
The top 7 journals account for 50% of the predicted probability mass.
1
The Lancet Infectious Diseases
○
73 papers in training set
Top 0.1%
16.5%
Similar papers in this journal
2
Nature Communications
○
5641 papers in training set
Top 19%
9.4%
Similar papers in this journal
- Resistance of Omicron subvariants BA.2.75.2, BA.4.6 and BQ.1.1 to neutralizing antibodies 96%
- Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine 96%
- Emergence of transmissible SARS-CoV-2 variants with decreased sensitivity to antivirals in immunocompromised patients with persistent infections 95%
4
Signal Transduction and Targeted Therapy
○
30 papers in training set
Top 0.1%
6.5%
Similar papers in this journal
- Robust Neutralization of SARS-CoV-2 Variants Including JN.1 and BA.2.87.1 by Trivalent XBB Vaccine-Induced Antibodies 96%
- ACE2-Targeting Monoclonal Antibody as Potent and Broad-Spectrum Coronavirus Blocker 93%
- Heterogeneous hybrid immunity against Omicron variant JN.1 at 11 months following breakthrough infection 93%
5
Cell Reports Medicine
○
153 papers in training set
Top 0.5%
4.7%
Similar papers in this journal
- Antibody escape drives emergence of diverse spike haplotypes resembling variants of concern in persistent SARS-CoV-2 infections 94%
- Clinical course impacts early kinetics and long-term magnitude and amplitude of SARS-CoV-2 neutralizing antibodies beyond one year after infection 94%
- Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4 and BA.5 in patients receiving monoclonal antibodies 94%
50% of probability mass above
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.